Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures (PROTECT)
Recruitment status was Recruiting
The purpose of this study is to determine the need for thromboprophylaxis in patients with a fracture of the lower extremity being treated conservatively in a below-knee plaster cast and to assess if both of the two tested prophylactic treatments are effective for this indication.
Nadroparine and Fondaparinux are both effective in preventing a thromboembolic event in patients with a nonsurgical fracture of a lower extremity immobilised in a below-knee plaster cast.
Deep Vein Thrombosis
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Prophylaxis of Venous Thromboembolism in Patients With a Nonsurgical Fracture of the Lower Extremity Immobilised in a Below-Knee Plaster Cast|
- Primary outcome measure is deep vein trombosis as detected by venous duplex [ Time Frame: subjects are assessed after 6 weeks ] [ Designated as safety issue: No ]
- Bleeding complications [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||April 2009|
|Estimated Study Completion Date:||April 2013|
|Estimated Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
No Intervention: 1
Patients randomized to the no intervention group
Subjects randomized to group receiving nadroparin 0,3 cc daily during immobilization
nadroparin 0,3 cc once daily during immobilization period
Other Name: Fraxiparin
Subjects randomized to fondaparinux 2,5 mg daily group during immobilization
Fondaparinux 2,5 mg daily during immobilization period
Other Name: Arixtra
A prospective, randomised, controlled, single blinded, multi-centre trial.
After meeting the inclusion criteria stated above and obtaining informed consent, patients will be randomly assigned to three groups: one receiving Nadroparine (2850 IE anti-Xa = 0,3 ml, given once daily), one receiving Fondaparinux (2,5 mg = 0,5 ml, given once daily) and one receiving no prophylaxis. These dosages are standard for the use in thromboprophylaxis. The first two groups will be instructed by a trained nurse in subcutaneous self-injection of the medicine and will be given pre-filled disposable syringes for once-daily administration for the duration of immobilisation.
In the light of current scientific knowledge a placebo effect of subcutaneous injections of saline in the control group is implausible since the outcome measure (colour duplex sonography) is an objective one.
Patients further will receive a letter explaining the symptoms suggesting the development of deep-vein thrombosis, pulmonary embolism and adverse events and will be asked to contact the emergency room when any of these would occur.
All patient-information will be coded so that it cannot be traced back to the individual patient. This coded information can be used for publication.
At the time of removal of the plaster cast symptoms or signs suggestive of DVT will be noted and a colour duplex ultrasonography of the treated limb will be performed in all patients by an experienced technician according to a strict diagnostic test protocol (see enclosure 1). When there is incompressibility of a vein or lack of flow the diagnosis of DVT is made. The technician will be blinded to treatment.
In case of a suspected pulmonary embolism pulmonary angiography will be performed.
The following risk-factors for DVT will be recorded: age, sex, body mass index (BMI), current smoking, use of estrogen-containing hormonal replacement therapy or oral contraception, active cancer (treatment on going or stopped for less than one year), congenital or acquired hypercoagulable state, previous deep venous thromboembolism and varicose veins.
Safety will be assessed as a secondary outcome. Adverse events such as haematomas, bleeding and allergic reactions will be recorded.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00881088
|Contact: Robert J Derksen, MD, PhD||+31 6 email@example.com|
|Contact: Roelf S Breederveld, MD, PhD||+31 251 firstname.lastname@example.org|
|University Medical Center Nijmegen||Recruiting|
|Nijmegen, Gelderland, Netherlands|
|Contact: Jan Paul Frolke, MD, PhD|
|VU University Medical Center||Recruiting|
|Amsterdam, N-Holland, Netherlands, 1117 MB|
|Contact: Fred C Bakker, MD, PhD +31 20 4444444 ext 097 email@example.com|
|Contact: Jels Fongers, MD +31 20 4443636 J.Fongers@vumc.nl|
|Red Cross Hospital||Recruiting|
|Beverwijk, N-Holland, Netherlands, 1942 LE|
|Contact: Robert J Derksen, MD, PhD +31 6 24748122 firstname.lastname@example.org|
|Contact: Roelf S Breederveld, MD, PhD +31251264920|
|Medical Center Alkmaar||Recruiting|
|Alkmaar, North Holland, Netherlands, 1815 JD|
|Contact: J H van der Brand, MD, PhD|
|Hoofddorp, North Holland, Netherlands, 2134 TM|
|Contact: Nico Sosef, MD|
|Study Director:||Roelf S Breederveld, MD, PhD||Red Cross Hospital Beverwijk|
|Principal Investigator:||Yannick M Groutars, MD||Red Cross Hospital Beverwijk|